Systemic administration of a novel development candidate, MTL-CEBPA, up-regulates the liver-enriched transcription factor C/EBP-alpha and reverses CCl4-induced liver failure in vivo.

臺大醫院;臺大醫院-外科部;臺大醫院-肝炎研究中心;臺大醫學院-臨床醫學研究所;Reebye, VikashVikashReebyeVoutila, JonJonVoutilaHuang, Kai-WenKai-WenHuangMuragundla, AnjaneyuluAnjaneyuluMuragundlaJayaprakash, AravindakshanAravindakshanJayaprakashVadnal, PrashantPrashantVadnalHuber, HansHansHuberHabib, RobertRobertHabibSaetrom, PalPalSaetromRossi, JohnJohnRossiHabib, NagyNagyHabib2017-06-222018-07-062017-06-222018-07-062015http://ntur.lib.ntu.edu.tw//handle/246246/279968Systemic administration of a novel development candidate, MTL-CEBPA, up-regulates the liver-enriched transcription factor C/EBP-alpha and reverses CCl4-induced liver failure in vivo.